
ARQT
Arcutis Biotherapeutics Inc
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.180
Open
13.500
VWAP
13.85
Vol
1.05M
Mkt Cap
1.63B
Low
13.435
Amount
14.50M
EV/EBITDA(TTM)
--
Total Shares
115.76M
EV
1.62B
EV/OCF(TTM)
--
P/S(TTM)
8.39
Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an established biological target in dermatology. It is also developing roflumilast cream for the treatment of atopic dermatitis. ZORYVE is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
84.50M
+18.41%
-0.087
-3.7%
78.26M
+74.86%
-0.110
-66.67%
70.91M
+129.79%
-0.153
-63.49%
Estimates Revision
The market is revising Upward the revenue expectations for Arcutis Biotherapeutics, Inc. (ARQT) for FY2025, with the revenue forecasts being adjusted by 4.12% over the past three months. During the same period, the stock price has changed by 20.92%.
Revenue Estimates for FY2025
Revise Upward

+4.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-20.97%
In Past 3 Month
Stock Price
Go Up

+20.92%
In Past 3 Month
8 Analyst Rating

35.57% Upside
Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 19.00 USD with a low forecast of 15.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy

35.57% Upside
Current: 14.015

Low
15.00
Averages
19.00
High
21.00

35.57% Upside
Current: 14.015

Low
15.00
Averages
19.00
High
21.00
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-09
Reason
Needham
Serge Belanger
Price Target
$20
2025-04-09
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$20
2025-04-03
Reason
Needham
Serge Belanger
Price Target
$20
2025-04-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$19
2025-04-03
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$19
2025-04-03
Reiterates
Strong Buy
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Reiterates
n/a
2025-04-03
Reason
Guggenheim
Seamus Fernandez
Price Target
n/a
2025-04-03
Reiterates
Strong Buy
Reason
Jefferies
Kambiz Yazdi
Strong Buy
Maintains
$16 → $19
2025-03-11
Reason
Jefferies
Kambiz Yazdi
Price Target
$16 → $19
2025-03-11
Maintains
Strong Buy
Reason
Jefferies raised the firm's price target on Arcutis Biotherapeutics to $19 from $16 and keeps a Buy rating on the shares. The firm views Arcutis as a beneficiary of a rotation to commercial from clinical biotech names given underlying market dynamics and market volatility shifting the risk profile lower, the analyst tells investors. Arcutis has demonstrated steady Zoryve growth and consistent quarterly beats, adds the analyst, who calls it a "GARP-y SMID-cap biotech."
Goldman Sachs
Jonathan Block
Hold
Maintains
$13 → $15
2025-02-27
Reason
Goldman Sachs
Jonathan Block
Price Target
$13 → $15
2025-02-27
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT.O) is -26.12, compared to its 5-year average forward P/E of -5.85. For a more detailed relative valuation and DCF analysis to assess Arcutis Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.85
Current PE
-26.12
Overvalued PE
-1.24
Undervalued PE
-10.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-4.66
Current EV/EBITDA
-19.89
Overvalued EV/EBITDA
-1.05
Undervalued EV/EBITDA
-8.27
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
183.91
Current PS
5.59
Overvalued PS
503.81
Undervalued PS
-135.99
Financials
Annual
Quarterly
FY2025Q1
YoY :
+32.84%
65.85M
Total Revenue
FY2025Q1
YoY :
-22.43%
-24.53M
Operating Profit
FY2025Q1
YoY :
-29.17%
-25.06M
Net Income after Tax
FY2025Q1
YoY :
-37.50%
-0.20
EPS - Diluted
FY2025Q1
YoY :
-1.95%
-30.99M
Free Cash Flow
FY2025Q1
YoY :
-7.32%
86.59
Gross Profit Margin - %
FY2025Q1
-54.83
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.3M
USD
17
3-6
Months
1.0M
USD
8
6-9
Months
1.7M
USD
13
0-12
Months
187.6K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
34.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.5M
Volume
4
6-9
Months
0.0
Volume
0
0-12
Months
2.3M
Volume
4
Bought
0-3
0
0.0
Volume
Months
3-6
4
955.9K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
10
11.6M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.3M
USD
17
3-6
Months
1.0M
USD
8
6-9
Months
1.7M
USD
13
0-12
Months
187.6K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
34.0K
USD
Months
0-12
0
0.0
USD
Months
ARQT News & Events
Events Timeline
2025-05-07 (ET)
2025-05-07
11:21:22
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements

2025-05-06 (ET)
2025-05-06
16:04:03
Arcutis Biotherapeutics reports Q1 EPS (20c), consensus (21c)

2025-04-10 (ET)
2025-04-10
16:37:32
Arcutis Biotherapeutics CFO David Topper to retire, Latha Vairavan to succeed

Sign Up For More Events
Sign Up For More Events
News
9.5
05-06Yahoo FinancePinnedArcutis Announces First Quarter 2025 Financial Results and Provides Business Update
9.5
05-06SeekingAlphaPinnedArcutis Biotherapeutics GAAP EPS of -$0.20 beats by $0.02, revenue of $65.8M beats by $3.32M
9.0
05-07NewsfilterPinnedArcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
Sign Up For More News
People Also Watch

BLDE
Blade Air Mobility Inc
2.935
USD
+5.96%

RLGT
Radiant Logistics Inc
6.010
USD
+0.84%

PBPB
Potbelly Corp
10.420
USD
+21.73%

SPOK
Spok Holdings Inc
16.620
USD
+0.85%

AUDC
AudioCodes Ltd
8.605
USD
+2.20%

CRVS
Corvus Pharmaceuticals Inc
3.420
USD
+6.88%

CMPS
Compass Pathways PLC
3.790
USD
+1.34%

LFVN
LifeVantage Corp
12.260
USD
+9.66%

TTSH
Tile Shop Holdings Inc
6.210
USD
+15.00%

MEC
Mayville Engineering Company Inc
14.220
USD
+10.66%
FAQ

What is Arcutis Biotherapeutics Inc (ARQT) stock price today?
The current price of ARQT is 14.015 USD — it has increased 2.3 % in the last trading day.

What is Arcutis Biotherapeutics Inc (ARQT)'s business?

What is the price predicton of ARQT Stock?

What is Arcutis Biotherapeutics Inc (ARQT)'s revenue for the last quarter?

What is Arcutis Biotherapeutics Inc (ARQT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arcutis Biotherapeutics Inc (ARQT)'s fundamentals?

How many employees does Arcutis Biotherapeutics Inc (ARQT). have?
